EZH2 does it

Because of the link between overexpression of the histone-methylating enzyme EZH2 and cancer, many researchers were surprised by a February paper that showed mutations in the histone methyltransferase actually inactivated the enzyme in B cell lymphomas. Now, Epizyme Inc.has painted a more complete picture by showing that these EZH2 mutations also can lead to an increase in activity.¹

With small molecule inhibitors of EZH2 (enhancer of zeste homolog 2) in hand, Epizyme will now put its findings to the test in mouse models of lymphoma and other EZH2-associated cancers...